Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2080 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale:

According to the latest National Survey on Care-Related Adverse Events, anticoagulants, including vitamin K antagonists (VKAs), rank first among medications responsible for serious iatrogenic accidents (37% in 2004, 31% in 2009). The EMIR study (2007) showed that VKAs were the leading cause of hospitalization for adverse effects (12.3%), with approximately 5,000 fatal hemorrhage-related accidents annually. Treatment and prevention of thromboembolic events represent a major public health challenge due to increased mortality, severity of functional sequelae, growing number of patients requiring treatment, and medical, social, and economic consequences. In 2013, an estimated 3.12 million patients received anticoagulation (4-5% of the French population). Several types of adverse events under oral anticoagulation appear to have high incidence in emergency settings: traumatic hemorrhage, spontaneous hemorrhage, asymptomatic overdose, and thrombosis. Different variables are associated with these events in patients admitted to emergency departments under oral anticoagulant treatment, but few studies have been conducted in real-world settings with large patient samples.

Hypothesis:

Iatrogenic events have a high incidence in patients admitted to emergency departments under oral anticoagulants and are a factor in early and late morbidity and mortality.

Primary Objective:

To describe the characteristics of patients admitted to the emergency department on oral anticoagulant therapy, with a particular focus on characterizing those presenting with Adverse Drug Events (ADEOA).

Study Design:

* Type: Observational, descriptive study
* Duration: 36 months total (24 months for data collection, 12 months for analysis)
* Sample Size: Estimated 2,080 patients (approximately 20 patients/week over 2 years)

Inclusion Criteria:

* Age ≥18 years
* Admission to adult emergency department
* Study period: January 1, 2018 to December 31, 2019
* Current oral anticoagulation therapy with:

* Acenocoumarol (Sintrom®/Minisintrom®)
* Apixaban (Eliquis®)
* Dabigatran (Pradaxa®)
* Fluindione (Previscan®)
* Rivaroxaban (Xarelto®)
* Warfarin (Coumadine®)

Exclusion Criterion:

\- Discontinuation of anticoagulant therapy for more than 24 hours

Primary Outcome Measures:

1. Description of oral anticoagulant groups based on medication type
2. Characterization of Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department (ADEOA):

1. Presence of ADEOA:

* Traumatic hemorrhage: acute bleeding following recent trauma
* Spontaneous hemorrhage: acute bleeding unrelated to recent trauma
* Asymptomatic overdose: INR \>3 for vitamin K antagonist patients
* Thrombosis: new arterial or venous thrombosis despite ongoing anticoagulation
2. Absence of ADEOA

Secondary Outcome Measures:

1. Assessment of adherence to oral anticoagulant prescribing guidelines
2. Identification of etiological factors for anticoagulation-related adverse events
3. Identification of early morbidity and mortality risk factors
4. Evaluation of medical-economic impact of adverse events and cost-effectiveness analysis of adverse events
5. Quality of life assessment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants

NCT02720328

Embolism and Thrombosis Hemorrhage

COMPLETED PHASE4

Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine

NCT03914053

Thromboembolism

COMPLETED

Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry

NCT04195113

Atrial Fibrillation Venous Thromboembolism Arterial Vascular Disease

COMPLETED

Risk of Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs

NCT02481011

Intracranial Hemorrhages Stroke

COMPLETED

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

NCT02319460

Hemorrhage

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemorrhage Thrombosis Anticoagulant Therapy Traumatic Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral anticoagulant therapy

anti-vitamin K or direct oral anticoagulants therapy

No interventions assigned to this group

No oral anticoagulant therapy

no anti-vitamin K or direct oral anticoagulants therapy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* Admission to adult emergency department of Besançon University Hospital
* Study period: January 1, 2018 to December 31, 2019
* Current oral anticoagulation therapy with:

* Acenocoumarol
* Apixaban
* Dabigatran
* Fluindione
* Rivaroxaban
* Warfarin

Exclusion Criterion:

\- Discontinuation of anticoagulant therapy for more than 24 hours

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No